PortalPublikationenMetyrapone tests in patients with panic disorder.

Metyrapone tests in patients with panic disorder.

Standard

Metyrapone tests in patients with panic disorder. / Kellner, Michael; Schick, Mildred; Yassouridis, Alexander; Struttmann, Tobias; Wiedemann, Klaus; Alm, Barbara.

in: BIOL PSYCHIAT, Jahrgang 56, Nr. 11, 11, 2004, S. 898-900.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Kellner, M, Schick, M, Yassouridis, A, Struttmann, T, Wiedemann, K & Alm, B 2004, 'Metyrapone tests in patients with panic disorder.', BIOL PSYCHIAT, Jg. 56, Nr. 11, 11, S. 898-900. <http://www.ncbi.nlm.nih.gov/pubmed/15576069?dopt=Citation>

APA

Kellner, M., Schick, M., Yassouridis, A., Struttmann, T., Wiedemann, K., & Alm, B. (2004). Metyrapone tests in patients with panic disorder. BIOL PSYCHIAT, 56(11), 898-900. [11]. http://www.ncbi.nlm.nih.gov/pubmed/15576069?dopt=Citation

Vancouver

Kellner M, Schick M, Yassouridis A, Struttmann T, Wiedemann K, Alm B. Metyrapone tests in patients with panic disorder. BIOL PSYCHIAT. 2004;56(11):898-900. 11.

Bibtex

@article{f2695a89fedc476a9d8388187e13786d,
title = "Metyrapone tests in patients with panic disorder.",
abstract = "BACKGROUND: Studies of hypothalamic secretion of corticotropin-releasing hormone (CRH) in patients with panic disorder in the nonpanic state (using CRH tests) are contradictory. No data about the hypothalamic-pituitary response to metyrapone are available. METHODS: Study participants included 14 patients with panic disorder (DSM-IV criteria) and 14 healthy control subjects who underwent a standard overnight metyrapone test and a combined metyrapone/low-dose dexamethasone test. RESULTS: Significant treatment effects of metyrapone and combined metyrapone/dexamethasone were found on plasma corticotropin, cortisol, and 11-deoxycortisol, but no differences between patients and control subjects emerged. Considering visual analogue scale ratings of anxiety, tension, restlessness, and Beck Depression Inventory scores as covariates, no group effects were detected. CONCLUSIONS: Standard overnight metyrapone tests do not support a hypersecretion of hypothalamic CRH in panic disorder. Furthermore, no evidence for increased glucocorticoid negative feedback in panic was found. Hypothalamic CRH secretion in the nonpanic state needs further research.",
author = "Michael Kellner and Mildred Schick and Alexander Yassouridis and Tobias Struttmann and Klaus Wiedemann and Barbara Alm",
year = "2004",
language = "Deutsch",
volume = "56",
pages = "898--900",
journal = "BIOL PSYCHIAT",
issn = "0006-3223",
publisher = "Elsevier USA",
number = "11",

}

RIS

TY - JOUR

T1 - Metyrapone tests in patients with panic disorder.

AU - Kellner, Michael

AU - Schick, Mildred

AU - Yassouridis, Alexander

AU - Struttmann, Tobias

AU - Wiedemann, Klaus

AU - Alm, Barbara

PY - 2004

Y1 - 2004

N2 - BACKGROUND: Studies of hypothalamic secretion of corticotropin-releasing hormone (CRH) in patients with panic disorder in the nonpanic state (using CRH tests) are contradictory. No data about the hypothalamic-pituitary response to metyrapone are available. METHODS: Study participants included 14 patients with panic disorder (DSM-IV criteria) and 14 healthy control subjects who underwent a standard overnight metyrapone test and a combined metyrapone/low-dose dexamethasone test. RESULTS: Significant treatment effects of metyrapone and combined metyrapone/dexamethasone were found on plasma corticotropin, cortisol, and 11-deoxycortisol, but no differences between patients and control subjects emerged. Considering visual analogue scale ratings of anxiety, tension, restlessness, and Beck Depression Inventory scores as covariates, no group effects were detected. CONCLUSIONS: Standard overnight metyrapone tests do not support a hypersecretion of hypothalamic CRH in panic disorder. Furthermore, no evidence for increased glucocorticoid negative feedback in panic was found. Hypothalamic CRH secretion in the nonpanic state needs further research.

AB - BACKGROUND: Studies of hypothalamic secretion of corticotropin-releasing hormone (CRH) in patients with panic disorder in the nonpanic state (using CRH tests) are contradictory. No data about the hypothalamic-pituitary response to metyrapone are available. METHODS: Study participants included 14 patients with panic disorder (DSM-IV criteria) and 14 healthy control subjects who underwent a standard overnight metyrapone test and a combined metyrapone/low-dose dexamethasone test. RESULTS: Significant treatment effects of metyrapone and combined metyrapone/dexamethasone were found on plasma corticotropin, cortisol, and 11-deoxycortisol, but no differences between patients and control subjects emerged. Considering visual analogue scale ratings of anxiety, tension, restlessness, and Beck Depression Inventory scores as covariates, no group effects were detected. CONCLUSIONS: Standard overnight metyrapone tests do not support a hypersecretion of hypothalamic CRH in panic disorder. Furthermore, no evidence for increased glucocorticoid negative feedback in panic was found. Hypothalamic CRH secretion in the nonpanic state needs further research.

M3 - SCORING: Zeitschriftenaufsatz

VL - 56

SP - 898

EP - 900

JO - BIOL PSYCHIAT

JF - BIOL PSYCHIAT

SN - 0006-3223

IS - 11

M1 - 11

ER -